Benzinga | Jun 2, 2021 06:43AM EDT

Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $125

Barclays analyst Travis Steed maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $150 to $125.